• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer.

作者信息

Baum M, Brinkley D M, Dossett J A, McPherson K, Patterson J S, Rubens R D, Smiddy F G, Stoll B A, Wilson A, Lea J C, Richards D, Ellis S H

出版信息

Lancet. 1983 Aug 20;2(8347):450. doi: 10.1016/s0140-6736(83)90406-3.

DOI:10.1016/s0140-6736(83)90406-3
PMID:6135926
Abstract
摘要

相似文献

1
Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer.早期乳腺癌乳房切除术后接受辅助性他莫昔芬治疗的患者生存率提高。
Lancet. 1983 Aug 20;2(8347):450. doi: 10.1016/s0140-6736(83)90406-3.
2
Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.他莫昔芬作为乳腺癌辅助化疗 - 内分泌治疗一部分的积极作用。北海道乳腺癌辅助化疗 - 内分泌治疗研究组。
Br J Cancer. 1994 Apr;69(4):767-71. doi: 10.1038/bjc.1994.145.
3
Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.接受辅助性他莫昔芬治疗的高危绝经后乳腺癌患者术后放疗：丹麦乳腺癌协作组DBCG 82c随机试验
Lancet. 1999 May 15;353(9165):1641-8. doi: 10.1016/S0140-6736(98)09201-0.
4
Tamoxifen with and without radiation after partial mastectomy in patients with involved nodes.有淋巴结转移的患者在保乳切除术后接受或不接受放疗时使用他莫昔芬的情况。
Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):777-81. doi: 10.1016/0360-3016(94)00499-4.
5
Tamoxifen.他莫昔芬
Lancet. 1983 May 28;1(8335):1199-200.
6
Limited surgery and tamoxifen in the treatment of elderly breast cancer patients.有限手术与他莫昔芬治疗老年乳腺癌患者
World J Surg. 2003 Feb;27(2):125-9. doi: 10.1007/s00268-002-6530-2.
7
Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation.
Lancet. 1983 Feb 5;1(8319):257-61.
8
A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer-final results at 20-year follow-up.仅行乳房切除术与他莫昔芬治疗可手术原发性老年乳腺癌患者的随机试验：20 年随访的最终结果。
Crit Rev Oncol Hematol. 2011 Jun;78(3):260-4. doi: 10.1016/j.critrevonc.2010.04.006. Epub 2010 May 5.
9
Six-year results of a controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer.
World J Surg. 1985 Oct;9(5):756-64. doi: 10.1007/BF01655191.
10
Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.接受乳房切除术及辅助化疗（使用或不使用他莫昔芬且未进行放疗）治疗的可手术乳腺癌患者的局部区域复发模式：五项国家外科辅助乳腺和肠道项目随机临床试验的结果
J Clin Oncol. 2004 Nov 1;22(21):4247-54. doi: 10.1200/JCO.2004.01.042. Epub 2004 Sep 27.

引用本文的文献

1
Evolution of Medical Approaches and Prominent Therapies in Breast Cancer.乳腺癌医学治疗方法及主要疗法的演变
Cancers (Basel). 2022 May 16;14(10):2450. doi: 10.3390/cancers14102450.
2
Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team.将科学偶然发现转化为乳腺癌研究和治疗的发现：一个博士生和一个 50 年漫游他莫昔芬团队的故事。
Breast Cancer Res Treat. 2021 Nov;190(1):19-38. doi: 10.1007/s10549-021-06356-8. Epub 2021 Aug 16.
3
Estimated Projection of US Cancer Incidence and Death to 2040.
预估 2040 年美国癌症发病与死亡人数。
JAMA Netw Open. 2021 Apr 1;4(4):e214708. doi: 10.1001/jamanetworkopen.2021.4708.
4
Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.长期暴露于雌激素可能通过表观遗传机制增强人乳腺癌细胞的化疗疗效。
PLoS One. 2017 Mar 21;12(3):e0174227. doi: 10.1371/journal.pone.0174227. eCollection 2017.
5
Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.他莫昔芬根据乳腺癌细胞的内分泌敏感性差异调节miR-29b-1和miR-29a的表达。
Cancer Lett. 2017 Mar 1;388:230-238. doi: 10.1016/j.canlet.2016.12.007. Epub 2016 Dec 13.
6
Roles for miRNAs in endocrine resistance in breast cancer.微小RNA在乳腺癌内分泌抵抗中的作用。
Endocr Relat Cancer. 2015 Oct;22(5):R279-300. doi: 10.1530/ERC-15-0355.
7
Progress in adjuvant chemotherapy for breast cancer: an overview.乳腺癌辅助化疗的进展：综述
BMC Med. 2015 Aug 17;13:195. doi: 10.1186/s12916-015-0439-8.
8
The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.雌激素剥夺治疗后靶向雌激素受体的分子、细胞及临床后果。
Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3(0 3):245-63. doi: 10.1016/j.mce.2015.06.004. Epub 2015 Jun 5.
9
Lost in translation: can we afford to miss the trees for the forest?翻译中的迷失：我们能承受只见森林不见树木之失吗？
Horm Cancer. 2014 Aug;5(4):203-6. doi: 10.1007/s12672-014-0187-9.
10
Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer.他莫昔芬作为乳腺癌的首个靶向长期辅助治疗药物。
Endocr Relat Cancer. 2014 May 6;21(3):R235-46. doi: 10.1530/ERC-14-0092. Print 2014 Jun.